Are scientists a workforce? - Or, how Dr. Frankenstein made biomedical research sick: A proposed plan to rescue US biomedical research from its current 'malaise' will not be effective as it misdiagnoses the root cause of the disease

The shift from quantitative to qualitative thinking-problems and prospects as viewed from Husserl's and Hegel's philosophy

This article contrasts the views of the philosophers Husserl and Hegel on quantification in science and compares their proposals for conducting rigorous qualitative research. Both deem quantification integral to science, but furthermore proposed methodologies to investigate qualitative necessities achieved by a shift in conscious activity and awareness. However, their methodologies differ significantly. While Husserl rejects idealization and instead proposes intuitive means to ideate qualitative essential relations, Hegel suggests idealizing less one-sidedly, namely, qualitatively over and above quantitatively. The article first examines how quantification is achieved and how it contrasts with measuring. This contrast reveals that measuring implies knowledge of qualities. These qualities, however, thus far remain oddly external to the mathematical relations linking the various established equations. The article then follows Husserl's reconstruction of the development of science to illustrate the dismissal of many experiential qualities and how philosophy further amplified skepticism about science on qualities. Husserl's notion of the life-world and the method of eidetic variation are then introduced as means to counterbalance mathematical proceedings in science. However, this method reveals both eidetic qualitative structures and psychical structures without being able to distinguish between them. It is thus susceptible to idiosyncratic, traditional, and cultural biases. Subsequently, Hegel's description of the shift in conscious experience that sets qualitative from quantitative thinking apart is introduced. This shift may overcome the biases, but it faces skepticism that calls for further investigation of the experience of different kinds of thinking.

[Can we save biomedical research from the managerial model?]

This article reflects on the disastrous effects that the managerial model had on contemporary biomedical research. It is argued that the time has come to reinvent an "antibureaucratic laboratory" which favors decision-making based on the intrinsic values of the researcher rather than the need to please external committees. Towards achieving this goal, governmental agencies should rely less on peer review and adopt new funding mechanisms. It is also predicted that the advent of the antibureaucratic laboratory" will only come at the cost of a revolution in the mentalities of all those involved in research.

Improving Translational Paradigms in Drug Discovery and Development

Despite improved knowledge regarding disease causality, new drug targets, and enabling technologies, the attrition rate for compounds entering clinical trials has remained consistently high for several decades, with an average 90% failure rate. These failures are manifested in an inability to reproduce efficacy findings from animal models in humans and/or the occurrence of unexpected safety issues, and reflect failures in T1 translation. Similarly, an inability to sequentially demonstrate compound efficacy and safety in Phase IIa, IIb, and III clinical trials represents failures in T2 translation. Accordingly, T1 and T2 translation are colloquially termed 'valleys of death'. Since T2 translation dealt almost exclusively with clinical trials, T3 and T4 translational steps were added, with the former focused on facilitating interactions between laboratory- and population-based research and the latter on 'real world' health outcomes. Factors that potentially lead to T1/T2 compound attrition include: the absence of biomarkers to allow compound effects to be consistently tracked through development; a lack of integration/'de-siloing' of the diverse discipline-based and technical skill sets involved in drug discovery; the industrialization of drug discovery, which via volume-based goals often results in quantity being prioritized over quality; inadequate project governance and strategic oversight; and flawed decision making based on unreliable/irreproducible or incomplete data. A variety of initiatives have addressed this problem, including the NIH National Center for Advancing Translational Sciences (NCATS), which has focused on bringing an unbiased academic perspective to translation, to potentially revitalize the process. This commentary provides an overview of the basic concepts involved in translation, along with suggested changes in the conduct of biomedical research to avoid valleys of death, including the use of Translational Scoring as a tool to avoid translational attrition and the impact of the FDA Accelerated Approval Pathway in lowering the hurdle for drug approval. © 2021 Wiley Periodicals LLC.

Mastomys Species as Model Systems for Infectious Diseases

Replacements of animal models by advanced in vitro systems in biomedical research, despite exceptions, are currently still not satisfactory in reproducing the whole complexity of pathophysiological mechanisms that finally lead to disease. Therefore, preclinical models are additionally required to reflect analogous in vivo situations as found in humans. Despite proven limitations of both approaches, only a combined experimental arrangement guarantees generalizability of results and their transfer to the clinics. Although the laboratory mouse still stands as a paradigm for many scientific discoveries and breakthroughs, it is mandatory to broaden our view by also using nontraditional animal models. The present review will first reflect the value of experimental systems in life science and subsequently describes the preclinical rodent model Mastomys coucha that-although still not well known in the scientific community-has a long history in research of parasites, bacteria, papillomaviruses and cancer. Using Mastomys, we could recently show for the first time that cutaneous papillomaviruses-in conjunction with UV as an environmental risk factor-induce squamous cell carcinomas of the skin via a "hit-and-run" mechanism. Moreover, Mastomys coucha was also used as a proof-of-principle model for the successful vaccination against non-melanoma skin cancer even under immunosuppressive conditions.

A new paradigm for the scientific enterprise: nurturing the ecosystem

The institutions of science are in a state of flux. Declining public funding for basic science, the increasingly corporatized administration of universities, increasing "adjunctification" of the professoriate and poor academic career prospects for postdoctoral scientists indicate a significant mismatch between the reality of the market economy and expectations in higher education for science. Solutions to these issues typically revolve around the idea of fixing the career "pipeline", which is envisioned as being a pathway from higher-education training to a coveted permanent position, and then up a career ladder until retirement. In this paper, we propose and describe the term "ecosystem" as a more appropriate way to conceptualize today's scientific training and the professional landscape of the scientific enterprise. First, we highlight the issues around the concept of "fixing the pipeline". Then, we articulate our ecosystem metaphor by describing a series of concrete design patterns that draw on peer-to-peer, decentralized, cooperative, and commons-based approaches for creating a new dynamic scientific enterprise.